VITURA

ASX:VIT

ASX ANNOUNCEMENT

INVESTOR WEBINAR

23 AUGUST 2023

Melbourne, Australia - Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to provide details of an investor webinar that will be held at the time and date set out below at which the Company's 2023 full year financial results will be presented.

The attached presentation will be used in the webinar.

Time and date: Monday, 28 August 2023 at 10.00 am (Melbourne time)

Link: https://kapara.rdbk.com.au/landers/bc54f7.html

** ENDS **











About Vitura Health Limited (ASX:VIT)

Vitura Health Limited is listed on the ASX (ASX:VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes 260+ product SKUs within Australia from 39 international and domestic medicinal cannabis brands.
 - o CanView is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The CanView system is based on a medicines wholesaling platform which seamlessly brings together a number of disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are a number of bespoke, internally-generated operating procedures and intellectual property assets, supported by the CanView customer support and infield customer engagement teams. Through the integration of the different elements which together make up CanView, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, CanView provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the CanView platform, without the need to input the patient's details. Prescriptions are then sent directly to the CanView patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the 3,600+ Australian pharmacies with accounts on CanView for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE:MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

www.vitura.com.au www.canview.com.au www.burleighheadscannabis.com www.cortexa.com.au www.cdaclinics.com.au www.cannadoc.com.au



Authorised by

Rodney Cocks, Chief Executive Officer and Executive Director

Contact

Vitura Health Limited

Rodney Cocks Chief Executive Officer and Executive Director 1300 799 491

info@vitura.com.au

Media enquiries

Tim Fogarty
The Civic Partnership
+61 400 179 075

tim.fogarty@civicpartners.com.au

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.



FY2023 FULL YEAR FINANCIAL REPORT INVESTOR PRESENTATION

23 AUGUST 2023

Innovating the delivery of healthcare

Investment Highlights and Results - Full Year FY2023

Digital health platform company with outstanding growth in FY2023, well positioned for FY2024 growth

Market leading, profitable and growing digital health company with a deep moat around the CanView business model

Profitable, highly cash generative, dividend paying

- o Outstanding, profitable growth in FY2023
- o FY2023 **Revenue \$117.34m** (75% growth on pcp)
- o FY2023 **Net profit after tax \$13.75m** (129% growth on pcp)
- o FY2023 **Cash at bank \$18.85m** (17% growth on pcp)
- o FY2023 **Units sold 945,000** (94% growth on pcp)
- Second 1c fully franked dividend declared

CanView - The market leading medicinal cannabis platform

- CanView enables the regulatory compliant prescription, sale and distribution of medicinal cannabis products through its automated, AI enabled and scalable digital health platform
- Launched in 2020 the CanView platform is becoming the industry standard for patients, prescribers, pharmacies and suppliers

Strong market growth² continuing and mainstreaming

- Estimated 41% HoH growth in medicinal cannabis retail spend by patients at pharmacies. Spend estimated to be \$200m at the end of FY2023
- At current estimated growth rates, the market is predicted to grow to nearly \$600m by the end of H1 FY20252
- Increases indicate a mainstreaming of cannabinoid therapies with patients and healthcare professionals

Operational leverage demonstrated during FY2023

- NPAT increase of 129%, as compared to revenue growth of 75% demonstrates achievement of significant operational leverage and sound cost containment
- Personnel costs increased by less than 20%, despite NPAT increasing by 129%

Deep competitive advantages; prescribers, patients, pharmacies

- CanView's competitive advantages include
 - o 1,000+ registered prescribers (Approx. 3% of all GPs nationally)¹
 - 8,000+ registered patients
 - 4,000+ pharmacies (70%+ of all pharmacies nationally)
 - o 260+ products from 39 leading international and domestic brands
- CanView 2.0 delivers clear network effects for platform users

Substantial growth opportunity, clear strategy to win

- Vision26, our 3-year growth strategy, has been implemented and we are executing against strategic priorities out to the end of FY2026
- FY2024 strategic priorities are focused on leveraging Vitura's expanded team of medical science liaisons to onboard more prescribers, and therefore, patients, across Australia implementing a data driven engagement strategy
- Inorganic growth through M&A, if shareholder value accretive and synergies exist with business model

^{1.} TGA, https://www.health.gov.au/health-topics/doctors-and-specialists/in-australia

^{2.} Penington Institute, Cannabis in Australia 2022, https://www.penington.org.au/cannabis/cannabis-reports-submissions/



Financial Highlights - Full Year FY2023

A record year on all metrics, with total Revenue of \$117m+ and NPAT of nearly \$14m

Significant, double and triple figure, growth of all major financial metrics in FY2023 compared to FY2022

	FY2023	Movement	FY2022	
Revenue	\$117.34m	75% 🛕	\$66.99m	
EBITDA	\$20.74m	98% 🛕	\$10.46m	
Net Profit After Tax	\$13.75m	129% 📥	\$6.01m	
Earnings per Share	2.49 cents	99% 🛕	1.25 cents	
Cash at Bank	\$18.85m	17% 🛕	\$16.08m	
Units Sold via CanView	945,000 units	94% 🛕	486,000 units	

Second fully franked 1.0c dividend declared and DRP


Based on Vitura's record FY2023, the Board has resolved to pay a fully franked dividend for the second consecutive year – rewarding shareholders in a very tangible way



The Board of Vitura Health will look to assess the payment of any future dividends within a capital management framework alongside other potential investment and growth opportunities that may be available to the Company, with a view to create and maximizing shareholder value

Significant revenue growth over the full FY2023

A record full year, with Revenue growing at a Compound Annual Growth Rate of 132%



- H2 FY2023 was focused on development and rollout of the CanView 2.0 platform, positioning VIT for continued growth in FY2024
- Revenue continues to grow as more prescribers and patient are onboarded to the CanView platform, loading up the flywheel
- The **network effect** on the platform is clear and continues to increase as more users are onboarded, which we expect to accelerate with the full roll out of the final **CanView 2.0**functionality stages during H1 FY2024
- The market we operate in continues to grow, with an increasing volume of prescriptions being directed through CanView by prescribers and pharmacies
- This revenue is being achieved with an estimated
 3%+ of all Australian GPs on the CanView platform
 significant opportunity remains to be captured



Profit and Loss Statement - nearly \$14m of NPAT

Significant operational leverage generated in addition to 129% growth in Net Profit After Tax

Continuing operations	30 June 2023 (\$'000s)	30 June 2022 (\$'000s)
Revenue	117,344	66,992
Cost of sales	(76,803)	(41,565)
Gross profit	40,541	25,427
Other income	416	264
Administration expenses	(3,734)	(2,531)
Finance costs	(226)	(441)
Information technology expenses	(1,592)	(488)
Legal and regulatory expenses	(1,032)	(446)
Personnel expenses	(13,776)	(11,511)
Sales and marketing expenses	(543)	(529)
Profit before income tax	20,054	9,745
Income tax expense	(6,304)	(3,732)
Profit for the year	13,750	6,013

- Year-on-year revenue growth of 75% driven by significant increase in unit sales
- Average gross margin across portfolio of 260+ SKUs maintained at nearly 34%
- NPAT increase of 129%, as compared to revenue growth of 75% demonstrates achievement of significant operational leverage and sound cost containment
- Personnel costs increased by less than 20%, despite NPAT increasing by 129%
- Product mix skewing towards products from third-party suppliers
- Administration cost increases due to depreciation of MDC and insurance
- o IT costs attributable to CanView 2.0 development
- Majority of carried forward tax losses recouped during FY2023
- **Significant interest income** of \$330,000 likely to increase further in FY2024

Strong balance sheet with no debt provides flexibility

Increasing net assets and nearly \$19m of cash at year end provide organic and inorganic growth options

Assets	30 June 2023 (\$'000s)	30 June 2022 (\$'000s)	Liabilities and equity	30 June 2 <mark>023</mark> (\$'000s)	30 June 2022 (\$'000s)
Current assets			Current liabilities		
Cash and cash equivalents	18,849	16,077	Trade and other payables	9,849	9,557
Trade and other receivables	9,335	5,759	Interest-bearing liabilities	238	489
Inventories	6,909	5,030	Current tax liabilities	244	1,662
Other assets	912	721	Employee benefit provisions	538	463
Total current assets	36,005	27,587	Total current liabilities	10,869	12,171
Non-current assets			Non-current liabilities		
Property, plant and equipment	1,240	624	Interest-bearing liabilities	1,041	4,570
Right-of-use assets	1,173	4,961	Deferred tax liabilities	84	50
Intangible assets and goodwill	7,103	7,158	Total non-current liabilities	1,125	4,620
Deferred tax assets	1,004	1,938	Equity		
Other assets	371	598	Share capital	24,042	22,776
Total non-current assets	10,891	15,279	Reserves	(3,803)	(3,148)
Total assets	46,896	42,866	Retained earnings	14,741	6,475
			Non-controlling interests	(78)	(28)
o FY2023 Net assets increase	ed by nearly 34 9	%+ to \$35m	Total equity	34,902	26,075

- o FY2023 Net assets increased by nearly 34%+ to \$35m
- o Solid cash balance of nearly \$19m provides maximum flexibility
- o Increase in inventories and plant attributable to **new MDC**
- o Significant decrease in right-of-use assets and interest-bearing liabilities due to timing of lease expiry and execution

Total liabilities and equity

42,866

46,896

Cash balance increases to record levels at nearly \$19m

Cash balance continues to grow even after paying \$12.3m in tax and dividends during FY2023

Cash flows from operating activities	30 June 2023 (\$'000s)	30 June 2022 (\$'000s)				
Receipts from customers	123,658	69,607				
Payments made to suppliers and employees	(107,218)	(55,473)				
Net interest received / (paid)	56	(89)				
Income tax paid	(6,788)	(540)				
Net cash flows from operating activities	9,708	13,505				
Cash flows from/(used in) investing activities						
Repayment/(payment) of security deposits	84	(311)				
Other net inflows from investing activities	7	208				
Purchases of plant and equipment	(928)	(365)				
Cash acquired on merger with CDA Health Pty Ltd		2,465				
Net cash flows from/(used in) investing activities	(837)	1,997				
Cash flows from/(used in) financing activities						
Payment of dividend at one cent per share	(5,463)	-				
Lease payments	(635)	(318)				
Payment of transaction costs relating to issue of shares		(1,186)				
Net cash flows from/(used in) financing activities	(6,098)	(1,504)				
Net increase in cash and cash equivalents held	2,772	13,998				
Cash and cash equivalents at the beginning of the year	16,077	2,079				
Cash and cash equivalents at the end of the year	18,849	16,077				

- Highly cash generative business model with FY2023 cash receipts of \$124m up 77%+ on FY2022
- Plant and equipment purchases attributable to the new Melbourne Distribution Centre established in October 2022
- Payments to suppliers include additional inventory purchases to stock Melbourne Distribution Centre in order to fuel further growth
- Significant increases in tax paid in FY2023 impacts net cash generated from operating activities
- Maiden fully franked dividend with respect of FY2022 of nearly \$5.5m paid during FY2023

Vision26 - The strategy to deliver sustainable growth

Leveraging a successful FY2023, the Board and Executive Leadership Team have developed and implemented Vision26, our 3 year growth strategy with clearly defined strategic priorities for execution

FY2023 Growth and Operational Milestones

ACHIEVED Stages 1-4 of CanView 2.0 rolled out, with stages 5 and 6 in progress

ACHIEVED Melbourne Distribution Centre fully licensed, commission and operational

ACHIEVED FY2023 \$117.34m Revenue FY2023 \$20.74m EBITDA and \$13.75m NPAT

ACHIEVED Strong balance sheet with \$18.85m at FY end

1,000+ prescribers registered on CanView (Approx. 3% of all GPs in Australia)¹ 8,000+ patients registered on CanView 4,000+ pharmacies registered on CanView

ACHIEVED Proven team of 12+ MSLs to deliver growth

ACHIEVED Cortexa psychedelics JV executed

ACHIEVED

ACHIEVED

Tech and distribution JV executed with Releaf

VISION26

FY2024 and Beyond

3 year Growth Strategy for growth to the end of FY2026

Strategic Priorities for FY2024

- Focus on onboarding individual and groups of prescribers onto the CanView platform, against ambitious targets, and therefore increasing patient numbers
- This loads the platform flywheel generating additional revenue and increases networks effects for all CanView platform users
- Vitura's 12+ MSLs have nationwide coverage, engaging with GPs and clinic groups to drive prescriber numbers and pharmacies
- Data driven strategy to target areas of opportunity in urban and regional areas nationwide
- With pharmacies at a critical mass, the clear focus is more prescribers and patients

Inorganic growth through M&A, if shareholder value accretive and synergies exist with business model

1. TGA, https://www.health.gov.au/health-topics/doctors-and-specialists/in-australia

We are a growing, profitable, Australian market leader

As a market leading digital health platform company with financial strength and a large addressable market, Vitura is well positioned for further growth in FY2024 and beyond with our Vision26 strategy

- As a digital health platform business, Vitura Health has delivered outstanding, profitable growth in FY2023 with Revenues of \$117.34m that generated \$13.75m in NPAT
- o The CanView platform is the engine of growth for Vitura, already in its **second iteration with CanView 2.0** which offers platform users increased functionality driving prescriber and patient onboarding to load the platform flywheel and increase network effects
- o The medicinal cannabis market is large and growing, with estimated 41% HoH growth to the end of FY2023, resulting in the total estimated patient spend at pharmacy of \$200m, predicted to increase to nearly \$600m by the end of H1 FY2025¹
- We have developed and implemented our ambitious corporate growth strategy, Vision26, which maps out a clear growth path and the strategic priorities for the next 3 years, to the end of FY2026, to underpin sustainable profitability
- o Our nationwide telehealth clinic businesses, CDA Clinics and Cannadoc, support CanView to onboard additional patients to the platform
- o There is a deep competitive moat around the business model, with a dominant market position, 1,000+ prescribers, 8,000+ patients, 4,000+ pharmacies are onboarded to CanView with 260+ branded products from 39 leading domestic and international brands
- We have an aligned majority Independent Board and Executive Leadership Team, with proven execution capability to deliver on our Vision26 strategy












The market we operate in is large and growing rapidly

The medicinal cannabis market continues to grow rapidly in Australia, as cannabinoid therapies become mainstreamed for patients, prescribers and pharmacists



Source: Penington Institute. Cannabis in Australia 2022, https://www.penington.org.au/cannabis/cannabis-reports-submissions

We operate at the downstream end of the value chain

Vitura Health is focused on the high value, downstream end of the value chain for sustainable long-term growth and profitability – based on our market leading CanView platform



Challenges of being upstream in the value chain

- Many participants in a crowded market
- Large CAPEX and OPEX spend required to operate and scale upstream business models
- Significant execution risk due to nature of operation
- o Pricing pressure from low cost jurisdictions globally
- Aggressive competition putting pressure on margins locally

Benefit of being downstream in the value chain

- Asset light business model
- o Digital healthcare platform that can be scaled significantly
- Relatively low CAPEX and OPEX cost to scale
- Model can be exported to other jurisdictions and used for other products (as demonstrated with our Psychedelics JV)
- Highly cash generative business

What we do - a clear focus on the CanView platform

Laser focused on the CanView platform, products and our clinic businesses

Vitura Health delivers medicinal cannabis prescription, sales and distribution services for prescribers, patients, pharmacies and suppliers throughout Australia via its market leading digital health CanView platform

Platform and Products - CanView

- We operate Australia's largest digital health medicinal cannabis platform, CanView, which is an online ecosystem for sales, prescribing, distribution, dispensing and education
- 39 domestic and international brands trust CanView for the prescription, sale and distribution of their products
- Approx. 1.7m units sold through CanView to date
- CanView sells 260+ branded products, including medicinal cannabis oil and whole flower products

Clinics - CDA Clinics and Cannadoc

 We operate CDA Clinics and Cannadoc that offer nationwide telehealth services for patients seeking to access medicinal cannabis



1,000+ Prescribers Nationwide in all states and territories

4,000+ Pharmacies Nationwide in all states and territories

120+ team members, right sized to enable growth

Medical Science Liaison coverage Nationwide in all states and territories

Cortexa Psychedelics JV with PharmAla (CSE:MDMA)

On 02 May 2023 Vitura Health announced our JV with PharmAla Biotech - Cortexa. Which aims to be a leading supplier of both MDMA and Psilocybin in Australia

- Vitura Health and Canadian-based PharmAla Biotech (CSE:MDMA) have established a 50:50 joint venture, called Cortexa, which aims to become the leading supplier of psychedelics for research and therapeutic use in Australia
- On 3 February 2023, the Therapeutic Goods Administration (TGA) announced that, as from 1 July 2023, it will permit the prescribing of MDMA for the treatment of post-traumatic stress disorder and Psilocybin for treatment-resistant depression under the Authorised Prescriber scheme
- Cortexa will capitalise on the market-leading distribution and industry relationships of Vitura Health and the proven GMP manufacturing technologies of PharmAla Biotech
- Cortexa will generate revenues from the outset, with all sale orders for MDMA and Psilocybin by PharmAla for supply into Australia being transferred to Cortexa

- Cortexa will have exclusive rights to purchase both GMP MDMA and GMP Psilocybin from PharmAla for distribution in Australia (Products)
- o PharmAla is expected to become the first company in the world able to supply both GMP MDMA and Psilocybin ready for prescription use in Australia
- Cortexa will be the exclusive licence holder for PharmAla's owned and licensed manufacturing technology and intellectual property (IP) assets relating to MDMA in Australia to enable onshore MDMA manufacturing
- Cortexa is also anticipated to be the exclusive licence holder for PharmAla's licensed manufacturing technology and IP assets relating to Psilocybin in Australia to also enable onshore Psilocybin manufacturing







Tech and Distribution JV with Releaf franchise network

On 16 May 2023 we announced our nationwide JV with Releaf Group - Australia's Leading National Medical Cannabis Clinical Franchise Network

- Vitura Health and Australian-based Releaf Group have established an unincorporated joint venture, to combine the leading technology and distribution capabilities of Vitura through the CanView platform and the large network of franchise medical cannabis clinical services of Releaf
- The Joint Venture is expected to increase the volume of medicinal cannabis products prescribed and distributed through the CanView platform, and the number of patients and prescribers registered and using the platform's functionality
- A Releaf-branded version of Vitura's leading CanView platform will be developed for use by Releaf's prescribing doctors, dispensaries and patients
- Releaf's doctors will have access to the Releaf-branded CanView platform to prescribe a wide range of products via the CanView platform's e-prescribing functionality

- Releaf's dispensaries will also be able to dispense products through the Releaf-branded CanView platform. Releaf currently operates clinics and dispensaries in four locations, with ten more expected to be opened by the end of calendar 2023
- Releaf patients will benefit from registering on the Releaf-branded CanView platform and having access to the patient app and, in coming months, the patient treatment tracker app
- The Releaf joint venture is further validation of the market leading CanView platform, being the first branded deployment of the platform with the backing of two state-of-the-art distribution centres







The CanView platform - an online ecosystem

The CanView platform facilitates all aspects of the medicinal cannabis ecosystem for patients, prescribers, pharmacists and suppliers – with clear Network Effects

Referred Patient

Patient books a Prescriber appointment via CanView in person or via Telehealth

Cannabis Product

Treatment commences, and patient books follow up consultation via CanView

5 CANVIEW

CanView Registered Doctor

Doctor sends prescription, via CanView to any of CanView's 4,000+ pharmacies

CanView Distribution

CanView platform facilitates delivery of medicinal cannabis **product** to pharmacy

CanView Registered Pharmacy

Pharmacy orders prescribed product via CanView platform

CanView for Patients




CanView solves multiple problems for patients that were previously impossible, or very difficult to achieve, without the platform – user friendly interface, intuitive functionality, designed with the patient in mind

The number of Patients on CanView has grown significantly with 47% quarterly compound growth

CanView provides patients with solutions

- Feedback from Patients has focussed on the disjointed, slow nature of obtaining medicinal cannabis outside of CanView
- Lack of transparency and information has hampered patients in their journey to obtain products
- o Patients can use the portal or app to
 - o Order repeat medicinal cannabis products
 - Book follow up prescribers consults
 - Track product deliveries
 - Provide clinical feedback to their prescriber



1. During H2 FY2023 patients were transitioned to the CanView 2.0 app, on 23AUG23 the number of patients on the app is now over 8,000. Noting that since CanView was established it has supplied medicinal cannabis products to tens of thousands of patients. It is anticipated that the number of patients registered on the app will increase significantly over the coming periods

CanView for Prescribers



CanView allows prescribers to build their practice, makes prescribing streamlined and underpins their compliance obligations for regulators, including AHPRA and the TGA

Quarter on quarter the number of Prescribers grew at a compound rate of 33% to nearly 1,000 (only 3% of the total number of GPs in Australia)¹

CanView provides Prescribers with solutions

- CanView enables prescribers to build their practice on the platform
- Compliance is a key issue for prescribers as they are regulated by AHPRA and the TGA
- CanView underpins efficiency of the prescribing process to deliver optimal patient outcomes
- CanView retains prescribing documents for compliance purposes while integrating to all major practice management software
- Prescribers can seamlessly generate scripts/eScripts within CanView
- Real time inventory insight

Cumulative prescriber accounts on CanView



1. TGA, https://www.health.gov.au/health-topics/doctors-and-specialists/in-australia

CanView for Pharmacies




CanView enables pharmacies to build a dispensing business, and based on feedback from pharmacies it saves them time, delivers on compliance obligations and makes dispensing extremely efficient

CanView has onboarded more than 4,000+ Pharmacies in Australia or 70%+ of the market

CanView provides pharmacies with solutions

- Pharmacists can build a business with the CanView platform
- Compliance is a key issue for pharmacies as dispensing is completed on approval paperwork that can be retained in the platform for future compliance reviews
- CanView integrates with major dispensing software systems for efficient operation within busy pharmacies
- Real time inventory insight is available for pharmacies
- Using CanView, pharmacies can dispense more products, in a shorter time with compliance confidence

Cumulative pharmacy accounts on CanView H1 FY2021 - H2 FY2023







For suppliers, CanView generates sales, through prescriber scripts. Moreover, rather than waiting for monthly updates, CanView provides suppliers with real time data, transparency and forecasting insight


39 of the leading brands are onboarded on CanView, with unit sales growing at a quarterly compound rate of 66%

- To date over 1.7m units have been sold through CanView, with nearly 500,000 in H2 FY2023
- CanView generates sales for suppliers through prescriber scripts/eScripts written

CanView provides suppliers with solutions

- Transparency of inventory and sales insight is a key issue that suppliers have struggled with
- CanView provides real time inventory and sales data that is actionable insight for forecasting and manufacturing
- Numerous suppliers on CanView have seen a significant increase in unit sales based on the platform's network effect





Australia's leading brands have partnered with CanView

CanView is trusted by Australia's leading domestic and international brands to sell and distribute the widest range of medicinal cannabis products available, which currently numbers 39 brands

















































































Highly rigorous process to select and onboard suppliers onto the platform, the criteria assessed includes -

Consistency and continuity of product supply

Investment in medical science liaison teams

Strict product quality standards

Dedicated help desk in supplier company

The Team - Majority Independent Board and Executive

Strategy and execution focused

We have assembled an experienced, commercially-focused team to execute on the Vision26 strategy and create sustainable shareholder value over the long term. Experienced Independent Board combining deep business development, sales, distribution, branding and regulatory expertise in the healthcare and digital platforms. Commercial, execution-focused Executive Leadership Team to deliver the strategy and create value for shareholders.



Dr Simone ScovellIndependent
Non-Executive
Director and Chair

SYDNEY

- Leader in digital health, med tech
- Founder and CEO of **TOTIUM**
- Director experience on Federal Government and corporate boards



Dr Marcia Walker Independent Non-Executive Director

AUCKLAND

- General PracticeDoctor
- Board member of the New Zealand Medical Association
- Co-Founder of numerous medical clinic businesses



Jenelle Frewen Independent Non-Executive Director

CANBERRA

- Government relations expert
- Deep policy and engagement experience
- Principal consultant
 Precision Public
 Affairs



Rodney Cocks CSM

Executive Director &
Chief Executive
Officer

MELBOURNE

- Co-Founder of VIT
- Former roles in PE, Linfox, BostonConsulting Group
- Former Victorian
 Australian of the
 Year and
 Harvard Fellow



Guy Headley
Executive Director &
Chief Commercial
Officer

GOLD COAST

- Co-Founder of VIT
- Significant commercial and distribution experience
- Chair of industry body Emerging Therapeutics Association of Australia



Tom HowittChief Financial
Officer & Company
Secretary

MELBOURNE

- Former CFO of Global Kinetics Corporation, Genetic Technologies & Intermoco
- Chartered
 Accountant and former EY
 Manager



Ryan Tattle *Chief Revenue Officer*


GOLD COAST

- Drives CanView on a daily basis
- Expert in platform businesses
- Former start up experience in USA
- Operated online multi-sided platform marketplaces



Appendix 1 - CanView Overview and Benefits

CanView overview and benefits for prescribers, patients, pharmacists and suppliers in the prescription, sale and distribution of medicinal cannabis products





Free to use | The platform is free for all users to register and use

Compliance | Built in compliance processes for all prescribers, pharmacies and suppliers to fulfil their obligations with regulatory agencies (eg. TGA)

Education | Free comprehensive confident cannabis prescriber and confident cannabis dispenser proprietary courses available on the platform

Free Express Shipping | Same day dispatch if ordered before 1pm, and same day local delivery in Melbourne and SE Queensland

260+ Products | CanView has the largest product range in Australia

Live Support | Dedicated and experienced Australian based customer support team for patients, prescribers, pharmacists and suppliers

Business Continuity | Suppliers have stock held in two locations

Al/Machine Learning | Enabled to underpin user experience and compliance

Distribution Coverage | All states and territories in Australia

Appendix 2 - Disclaimer applying to this Presentation

The following disclaimer applies to this presentation (Presentation)

You are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any information contained in this Presentation. This Presentation has been prepared by Vitura Health Limited (Vitura or Company).

Not investment advice

The information contained in this Presentation is not investment or financial product advice or any recommendation to acquire Shares. This Presentation does not and will not form any part of any contract for the acquisition of Shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation.

Future performance

This Presentation contains forward looking statements and comments about future events, including Vitura's expectations about the performance of its business. Forward looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" and other similar expressions.

You are cautioned not to place undue reliance on any forward-looking statement. While due care and attention has been used in the preparation of forward-looking statements, forward looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends which are based on interpretations of current market conditions. Forward looking statements should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Vitura.

A number of important factors could cause the actual conduct, results, performance or achievement of Vitura to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. Actual results, performance or achievements may vary materially from any forward-looking statements and the assumptions on which statements are based. Vitura disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise.

The forward-looking statements are based on information available to Vitura as at the date of this Presentation. Except as required by law or regulation, Vitura undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Summary information

This Presentation contains summary information about Vitura and its activities which is current only as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Vitura or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth.) (Corporations Act).

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Vitura nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy.

Not an offer

This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction.

